FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2980804987> ?p ?o ?g. }

• W2980804987 endingPage "2837" @default.
• W2980804987 startingPage "2837" @default.
• W2980804987 abstract "Abstract PD-1 and MDSC are two recently discovered important tumor immune escape mechanisms. These immune escape pathways have been studied and their levels were found to be elevated in tumors such as myeloma, pancreatic, renal, ovarian, and breast cancers. Therefore, we studied these two immune escape pathways in patients with myeloid neoplasms including polycythemia vera (PV), Essential thrombocythemia (ET), myelofibrosis (MF) including primary myelofibrosis (PMF) and Post-ET, Post-PV myelofibrosis. We also studied IMID drug in vitro to see if IMID drug mechanism is related to these two escape pathways. 51 patients with MPN and 15 normal volunteer controls were studied. For quantification of expression of PD-1 and PD L-1 in MNC subpopulations (CD4+, CD8+ or CD14+ cells). Ficoll-paque- isolated MNCs were stained with PD-1(CD279-APC) and PD L-1 (CD274-PE)BD Biosciences; CA) plus either CD4-FITC, CD8-FITC or CD14-FITC, along with 7AAD (6 ug/ml), and subjected to flow cytometric analysis. The flow data was analyzed using FlowJo (v 7.6.2). PD-1 or PD L-1 positive cells were expressed as percentage in the subpopulation of cells assayed. For MDSC's, after Ficoll-Paque density centrifugation of peripheral blood, 106 mononuclear cells were stained for flow cytometric analysis using CD11b-APC, CD33-PE, and CD14-FITC (BD Biosceinces; Carlsbad, CA), along with their matched isoptoye controls. 7AAD (6 ug/ml) was used to exclude dead cells to eliminate nonspecific antibody binding. 50,000 events per specimen were acquired and the resultant flow cytometric data was analyzed by FlowJo software. MDSC's were defined as CD11b+CD14-CD33+ cells and were calculated as percentage of viable gated MNC's. MDSC's were also tested for in vitro inhibitory effects on Tcells : MDSC cell sorting was performed by flow cytometry of CD33+ cells from CD11b+CD14- microbead selected cells. CD3 cells were then labeled with CFSE (Life Technologies; CA) and incubated with and without the sorted MDSC's in the presence of CD3+CD28+ microbeads for five days before assessing CFSE activity. For IMID drug in vitro experiments, Pomalidomide (Pm)( Celgene) (10ϰg/ml) was added to mononuclear cells in the presence of CD3+CD28+ microbeads in culture medium. After 5-7 days, cells were assayed for PD-1, PD-L1 expression and MDSC's. Since our data showed no significant difference between ET, PV and MF, we grouped ET, PV and MF together as MPN. The results showed that there is no significant difference between patients with MPN and controls of PD-1 and PD-L1 expression in CD4+, CD8+ and CD14+ cells. However, MDSC's were significantly elevated in patients with MPN compared to controls (Fig 1.). Pomalidomide significantly reduced the expression of PD-1 and MDSC's- expressed as fold change of Pm/DMSO (mean+ SE) in CD4 +,( 0.46 ± 0.120, p= 0.05) , CD8+ (0.66±0.07,p=0.02), MDSC ( 0.71 ± 0.09, P=0.01). Pomalidomide has no significant effect on PD-1 expression in CD14+ cells and PD1-L-1 expression in CD4+, CD8+ and CD14 + cells .Sorted MDSC's significantly suppressed proliferation of the CFSE labeled CD3+ T cells. We conclude that 1) PD-1, PD L-1 expression is not altered in MPN patients. However, MPN patients have significantly increased MDSC's. 2) Pomalidomide, in vitro, significantly reduces the expression of PD-1 in CD4+, CD8+ cells and decreases MDSC. This data may be added to be one of the important mechanisms of immunomodulatory drugs in the treatment of Myelofibrosis. Disclosures: No relevant conflicts of interest to declare." @default.
• W2980804987 created "2019-10-25" @default.
• W2980804987 creator A5009218109 @default.
• W2980804987 creator A5033442992 @default.
• W2980804987 creator A5062206685 @default.
• W2980804987 creator A5073190439 @default.
• W2980804987 creator A5090345854 @default.
• W2980804987 date "2013-11-15" @default.
• W2980804987 modified "2023-10-01" @default.
• W2980804987 title "Programmed Cell Death Receptor (PD-1), PD-1 Ligand (PD-L1) Expression and Myeloid Derived Suppressor Cells (MDSC) In Myeloid Neoplasms Implicate The Mechanism Of IMiD Treatment Of Myelofibrosis" @default.
• W2980804987 doi "https://doi.org/10.1182/blood.v122.21.2837.2837" @default.
• W2980804987 hasPublicationYear "2013" @default.
• W2980804987 type Work @default.
• W2980804987 sameAs 2980804987 @default.
• W2980804987 citedByCount "9" @default.
• W2980804987 countsByYear W29808049872014 @default.
• W2980804987 countsByYear W29808049872015 @default.
• W2980804987 countsByYear W29808049872016 @default.
• W2980804987 countsByYear W29808049872017 @default.
• W2980804987 countsByYear W29808049872018 @default.
• W2980804987 countsByYear W29808049872019 @default.
• W2980804987 countsByYear W29808049872020 @default.
• W2980804987 countsByYear W29808049872023 @default.
• W2980804987 crossrefType "journal-article" @default.
• W2980804987 hasAuthorship W2980804987A5009218109 @default.
• W2980804987 hasAuthorship W2980804987A5033442992 @default.
• W2980804987 hasAuthorship W2980804987A5062206685 @default.
• W2980804987 hasAuthorship W2980804987A5073190439 @default.
• W2980804987 hasAuthorship W2980804987A5090345854 @default.
• W2980804987 hasConcept C10205521 @default.
• W2980804987 hasConcept C109316439 @default.
• W2980804987 hasConcept C167672396 @default.
• W2980804987 hasConcept C176290653 @default.
• W2980804987 hasConcept C182547069 @default.
• W2980804987 hasConcept C185592680 @default.
• W2980804987 hasConcept C202751555 @default.
• W2980804987 hasConcept C203014093 @default.
• W2980804987 hasConcept C2778513237 @default.
• W2980804987 hasConcept C2779282312 @default.
• W2980804987 hasConcept C2780007613 @default.
• W2980804987 hasConcept C2780076729 @default.
• W2980804987 hasConcept C28328180 @default.
• W2980804987 hasConcept C502942594 @default.
• W2980804987 hasConcept C553184892 @default.
• W2980804987 hasConcept C55493867 @default.
• W2980804987 hasConcept C71924100 @default.
• W2980804987 hasConcept C86803240 @default.
• W2980804987 hasConcept C8891405 @default.
• W2980804987 hasConcept C95444343 @default.
• W2980804987 hasConceptScore W2980804987C10205521 @default.
• W2980804987 hasConceptScore W2980804987C109316439 @default.
• W2980804987 hasConceptScore W2980804987C167672396 @default.
• W2980804987 hasConceptScore W2980804987C176290653 @default.
• W2980804987 hasConceptScore W2980804987C182547069 @default.
• W2980804987 hasConceptScore W2980804987C185592680 @default.
• W2980804987 hasConceptScore W2980804987C202751555 @default.
• W2980804987 hasConceptScore W2980804987C203014093 @default.
• W2980804987 hasConceptScore W2980804987C2778513237 @default.
• W2980804987 hasConceptScore W2980804987C2779282312 @default.
• W2980804987 hasConceptScore W2980804987C2780007613 @default.
• W2980804987 hasConceptScore W2980804987C2780076729 @default.
• W2980804987 hasConceptScore W2980804987C28328180 @default.
• W2980804987 hasConceptScore W2980804987C502942594 @default.
• W2980804987 hasConceptScore W2980804987C553184892 @default.
• W2980804987 hasConceptScore W2980804987C55493867 @default.
• W2980804987 hasConceptScore W2980804987C71924100 @default.
• W2980804987 hasConceptScore W2980804987C86803240 @default.
• W2980804987 hasConceptScore W2980804987C8891405 @default.
• W2980804987 hasConceptScore W2980804987C95444343 @default.
• W2980804987 hasIssue "21" @default.
• W2980804987 hasLocation W29808049871 @default.
• W2980804987 hasOpenAccess W2980804987 @default.
• W2980804987 hasPrimaryLocation W29808049871 @default.
• W2980804987 hasRelatedWork W1965676607 @default.
• W2980804987 hasRelatedWork W1987687208 @default.
• W2980804987 hasRelatedWork W1990381878 @default.
• W2980804987 hasRelatedWork W2002866812 @default.
• W2980804987 hasRelatedWork W2027824286 @default.
• W2980804987 hasRelatedWork W2037921517 @default.
• W2980804987 hasRelatedWork W2381239004 @default.
• W2980804987 hasRelatedWork W2561781137 @default.
• W2980804987 hasRelatedWork W4231983975 @default.
• W2980804987 hasRelatedWork W4313350083 @default.
• W2980804987 hasVolume "122" @default.
• W2980804987 isParatext "false" @default.
• W2980804987 isRetracted "false" @default.
• W2980804987 magId "2980804987" @default.
• W2980804987 workType "article" @default.